Advertisement

Topics

Oncolytics Company Profile

06:04 EST 22nd February 2019 | BioPortfolio

The Company's technologies are based on discoveries arising from research conducted at the University of Calgary. Dr. Coffey, VP Product Development for the Company was instrumental in these discoveries, and continues to be instrumental in the product development process.

The Company was formed in 1998, to explore the natural oncolytic capability of the reovirus, a virus that preferentially replicates in cells with an activated Ras pathway.



The product being developed by the Company may represent a novel treatment for certain tumor types and some cellular proliferative disorders. The Company’s product is a virus that is able to replicate specifically in, and hence kill, certain tumor cells both in tissue culture as well as in a number of animal models.



The Company’s product for human use, REOLYSIN®, is the reovirus. This virus has been demonstrated to replicate specifically in tumor cells bearing an activated Ras pathway. Activating mutations of Ras and upstream elements of Ras may play a role in greater than two thirds of all potential tumors.

Location

210, 1167 Kensington Crescent
NW Calgary
AB T2N 1X7

Contact

Phone: (403) 670-7377
Fax: (403) 283-0858
Email: dougballonc@aol.com


News Articles [41 Associated News Articles listed on BioPortfolio]

Oncolytics Biotech Appoints CMO

Dr. Rita Laeufle, M.D., Ph.D., had been working as a consultant for Oncolytics for the last four months

New Collaboration For Oncolytics Biotech and SOLTI

On Monday (September 10), Oncolytics Biotech (NASDAQ:ONCY, TSX:ONC) announced details of its new collaboration for its Phase 3 clinical trial. The post New Collaboration For Oncolytics Biotech and SOL...

Oncolytics Biotech Collaborates with SOLTI to Conduct a Window of Opportunity Study in Breast Cancer with Pelareorep

Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), currently developing REOLYSIN (pelareorep), an intravenously delivered immuno-oncolytic virus turning cold tumors hot, today announced a clinical col...

Oncolytics inks clinical collaboration pact with SOLTI to conduct WOO study in breast cancer with pelareorep

Oncolytics Biotech Inc, currently developing Reolysin (pelareorep), an intravenously delivered immuno─oncolytic virus turning cold tumours hot, announced a clinical collaboration with SOLTI, an acad...

Oncolytics Biotech Announces Positive Clinical Trial Results for Pelareorep in Patients with KRAS Mutant Metastatic Colorectal Cancer for Presentation at ESMO 2018

CALGARY, Alberta and SAN DIEGO, Oct. 22, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic vir...

Oncolytics Biotech Enters into Common Stock Purchase Agreement for up to US$26 Million with Lincoln Park Capital

Oncolytics Biotech (NASDAQ:ONCY,TSX:ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus turning cold tumors hot, today announced the execution of a Common Stock P...

Oncolytics Biotech® Establishes New At-The-Market Facility

CALGARY, Alberta and SAN DIEGO, Oct. 24, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic v...

Oncolytics Biotech® Provides Corporate and Clinical Update

- Webcast and conference call for investors and analystson Thursday, September 20 at 8:30 a.m. EDT - CALGARY, Alberta and SAN DIEGO, Sept. 19, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (...

Drugs and Medications [0 Results]

None

PubMed Articles [1 Associated PubMed Articles listed on BioPortfolio]

Lipopeptisomes: Anticancer Peptide-Assembled Particles for Fusolytic Oncotherapy.

Anticancer peptides (ACPs) are cationic amphiphiles that preferentially kill cancer cells through folding-dependent membrane disruption. Although ACPs represent attractive therapeutic candidates, part...

Clinical Trials [1 Associated Clinical Trials listed on BioPortfolio]

The Validation of a Novel Adherence Method for Oral Oncolytics

The long-term goal of this research is to apply technologic approaches to improve the use of oral oncolytics. The objective of this study is to assess patient adherence to oral oncolytics ...

Companies [2 Associated Companies listed on BioPortfolio]

Oncolytics Biotech Inc.

Oncolytics Biotech Inc. was formed in 1998 to develop its proprietary product, REOLYSIN®, as a potential therapeutic for a wide variety of human cancers. Oncolytics has completed five clinical trials...

Oncolytics

The Company's technologies are based on discoveries arising from research conducted at the University of Calgary. Dr. Coffey, VP Product Development for the Company was instrumental in these discoveri...

More Information about "Oncolytics" on BioPortfolio

We have published hundreds of Oncolytics news stories on BioPortfolio along with dozens of Oncolytics Clinical Trials and PubMed Articles about Oncolytics for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Oncolytics Companies in our database. You can also find out about relevant Oncolytics Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record